Clinical Trial Update: Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravitreal ranibizumab for macular edema due to retinal vein occlusion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Korea Ltd. | Conditions: Macular Edema, Retinal Vein Occlusion | Phase 3 | Status: COMPLETED